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Introduction
Gastric cancer (GC) is one of the commonest forms of ma-
lignancies in the world. Pathogenesis of gastric cancer is
associated with activation of oncogenes, inactivation of tu-
mor suppressor genes and deregulation of cellular signal
pathways. The gastric epithelial cells undergo stepwise
morphologic changes before malignant transformation and
multiple signaling pathways have been known to be in-
volved in this carcinogenic process. In tumor, a small sub-
population of transformed stem cell termed as cancer stem
cell plays significant role in maintenance of stemness as well
as survival of the tumor cells.
CXCR4 is a chemokine receptor and was first identified as a
regulator of the homing of lymphocytes in inflammatory
tissues.1 Stromal cell-derived factor (SDF)-1α is cognate lig-
and of CXCR4 and high levels expression of SDF1α /CXCR4
axis is associated with lung, liver and lymph nodes metasta-
sis.2 SDF1α /CXCR4 axis plays key role in human develop-
ment, including organogenesis, vascularisation, haematopoi-
esis, and embryogenesis.3 More recent evidence shows that
the SDF-1α /CXCR4 axis acts as key regulator of metastasis
in leukemia & several solid tumors and also plays an im-
portant role in self renewal, differentiation potential, cell
adhesion, tumorigenicity & tumor vascularization capacity of
tumor cell.4,5 CD133 is a 5-transmembrane cell surface gly-
coprotein expressed in subpopulation of CD34þ haematopoi-
etic stem and progenitor cells derived from human fetal liver
and bone marrow.6 CD133 expression has been detected in
normal tissues like neuroepithelium stem cells in mice, em-
bryonic & adult immature epithelia and also considered as
well studied cancer stem cell marker.7 Although the exact
function of CD133 expression in tumor tissues is still not
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clear however could serve as a prognostic indicator for tumor
re-growth, malignant progression, and patient survival. Ex-
pression of CD133 is involved in bioenergetic stress, re-
sistance to apoptosis and the activation of a stemness-related
signaling pathway.8 Various studies suggests that CSC
co-expressing CXCR4 and CD133 is highly tumorigenic, and
found to be expressed in malignant Rhabdoid tumor of the
kidney (MRTK) in infant, metastatic Pancreatic cancer, and
Renal cell carcinoma.9-11 In this study, immunohistochemis-
try and immunofluorescence method was used to study the
expression of CXCR4 and CD133 in gastric cancer. RT-PCR
also supports the expression pattern of these two regulatory
molecules. Discussion on the relationship of CXCR4 and
CD133 in gastric cancer tissues may be helpful to establish
the biological behaviour and prognosis of gastric cancer and
may also helpful for studying molecular drug targeting.
Methods and Materials
Study population and tissue specimens
The biopsy specimens of gastric cancer were obtained from
70 patients of Department of Gastroenterology, Stanley
Medical College and Hospital, Chennai, Tamil Nadu, India.
The study was approved by the ethics committee of the
Stanley Medical College and Hospital. Written informed
consents were obtained from all the patients for participation
in the study. Additionally 20 resected specimens following
gastrectomy for stomach malignancy were also included for
the study. Another 30 cases of adjacent normal gastric mu-
cosa (by gastroscopic biopsy) were used as control.
The study group was consisted of 90 patients, male 68 cases
and female 22 cases (25-75 years of age, the median age of 50
years). Stage, grade and histological types were defined after
histopathological examination. There were 25 cases of upper
gastric malignancy, 30 cases of middle malignancy and 35
cases of antral malignancy. In the all, 38 cases had tumor size
(<4 cm) and the other 24 cases had large tumor size >8 cm,
and 28 patients had tumour size in between 4-8 cm. There
were mucosal tumour 14 cases, 35 cases of sub mucosal tu-
mour, 26 cases of Muscularis Propia tumour and 15 cases of
Sub Serosa tumour. There were 54 cases with lymphatic in-
vasion and 51 cases with node metastasis of tumour. Patients
in the study group had no history of undergoing chemo-
therapy or radiation therapy.
Immunohistochemistry and immunofluorescence
study
Experimental paraffin block samples were used for serial
tissue sectioning, 4 μm thickness underwent HE, as well as
IHC staining respectively. The endogenous peroxidise activ-
ity was blocked by 3% H2O2 and non-specific binding was
blocked with 3% BSA in 1x PBS at room temperature. The
sections were then incubated overnight at 4°C with primary
antibodies for anti-CXCR4, and anti-CD133 (1:300), (Santa
Cruz Biotechnology-USA). The slides were washed in 1x PBS
and incubated with the corresponding secondary antibody
conjugated with HRP. The peroxidase reaction was devel-
oped by hydrogen peroxide in 1x PBS as substrate and
3,3´-diaminobenzidine tetrachloride as chromogen. The
sections were counter stained with Mayer’s haematoxylin
and mounted with DPX after proper dehydration. Positive
control sections were prepared to confirm the reactivity of
the antibody whereas negative control sections were pre-
pared by substituting PBS instead of primary antibody.
For immunofluorescence studies, after incubation with pri-
mary antibodies, fluorescent conjugated secondary antibod-
ies were used (FITC- conjugated anti-mouse for CXCR4 and
Alexa 592 (red) anti-goat for CD133) and later on the slides
were counterstained using DAPI. The sections were mount-
ed and examined under confocal microscopy (Leica TCS2-
XL Spectra confocal-Multiphoton microscopy).
Evaluation of immunostaining
The intensity and cellular localization of immunostained
CXCR4 and CD133 was evaluated in a semi-quantitative
fashion. Staining intensity was graded in 0-3 scale (0- no
staining, 1- shallow brown, 2- Brown, 3- dark brown). Posi-
tive cells were also graded in 0-3 scale (0- no staining, 1<
25% staining cells, 2< 25-50% staining cells and 3> 50%
staining cells). The final scores were given as -, +, ++ and +++
which were summation of staining percentages and intensi-
ty; and considered as negative, mild, moderate and intense
respectively. Distinct membranous to cytoplasmic expression
of CD133 was considered as positive expression whereas
discrete cytoplasmic expression was considered as positive
CXCR4.
Reverse transcriptase PCR
RNA was extracted using Isol-RNA Lysis Reagent (5’PRIME
Inc, Gaithersburg, USA) according to the manufacturer’s
protocol. The RNA concentration was determined by Bio-
photometer (Eppendorf, Germany) and total RNA (1 mg)
was used to generate cDNA using standard method. The
reactions were cycled after an initial denaturation at 94°C for
5 min followed by 39 cycles of denaturation at 94°C for 30
sec, annealing at 60°C for 30 sec, and polymerization at 72°C
for 60 sec. Final extension was done at 72°C for 5 min.
β-actin was used as housekeeping gene. The PCR products
were electrophoresed on 1.2% agarose gels with ethidium
bromide and visualized in UV light (VilberLourmat, France).
Statistical analysis
The χ2 test was used for the percentage of samples with pos-
itive staining among lesions of different histological grades
using StatCalc 5.0.4 (AcaStat software).The independent
student’s t-test was used for statistical significant in western
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blot analysis. p< 0.05* was considered statistically significant
and p< 0.01** was considered as highly significant.
Results
The expression of CXCR4 and CD133 in gastric cancer
and adjacent normal gastric mucosa
IHC assay showed that CXCR4 positive staining mainly lo-
calized on cell cytoplasm (Figure 1A), and brownish granule
of CD133-positive were visible in cytoplasm and the cell
membrane (Figure 1B), which both didn’t express in gastric
normal tissues. The positive rate of CXCR4 expression was
85/90 (94.44%) and 7/30 (23.23%) in gastric cancer and ad-
jacent normal tissues, with statistically significant differences
(p<0.001**) (Table 1). To CD133, positivity in gastric cancer
was 95.55% (86/90), very mild expression 5/30 (16.66%) in
the adjacent normal tissues was found, showing strong dif-
ferences (p<0.001**) (Table 2).
FIG. 1: Immunohistochemical analysis shows overexpression of CXCR4 and CD133 in human gastric cancer. A) Expression of CXCR4 mainly
localized in the cell cytoplasm; B) Positive staining of CD133 localized in cytoplasm and cell membrane. (Magnification in 20X).
TABLE 1: Expression of CXCR4 in gastric cancer and normal tissue.
Clinicopathological
stages
Differential expres-
sion pattern
Number of
cases (n=120)
Positive
rate%
χ2 p value
- + ++ +++
Normal gastric mucosa 23 7 0 0 30 23.23 -
Adenocarcinoma 5 12 26 47 90 94.44 74.516 0.000**
a. Calculated using χ2
b. 0.000 = <0.001** denotes significance at 1% level.
TABLE 2: Expression of CD133 in gastric cancer and normal tissue.
Clinicopathological
stages
Differential expres-
sion pattern
Number of
cases (n=120)
Positive
rate%
χ2 p value
- + ++ +++
Normal gastric mucosa 24 5 1 0 30 16.66 -
Adenocarcinoma 4 14 27 45 90 95.55 76.922 0.000**
a. Calculated using χ2
b. 0 .000 = <0.001** denotes significance at 1% level.
Coimmunolocalization of CXCR4 and CD133 in gastric
tissues
Coimmunofluorescence of CXCR4 and CD133 was per-
formed in normal and adenocarcinoma tissue sections of
gastric tissues (Figure 2). CXCR4 was conjugated with an-
ti-Mouse FITC (green) and CD133 with anti-Goat Alexa
fluor (red). Merged image shows yellow color which indi-
cates their colocalization. CXCR4 and CD133 were princi-
pally colocalized in cytoplasm of adenocarcinoma, while it
was not observed in normal tissues. This result showed in-
teresting evidence for intracellular convergence of CXCR4
and CD133 during gastric adenocarcinoma progression and
its prognosis (Figure 2).
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FIG. 2: Co-immunolocalisation of CXCR4 and CD133 in gastric epithelial tissue. The expression of both CXCR4 (A-B) and CD133 (C-D) in the
same field of gastric tissue by immunofluorescence using FITC (green) for CXCR4 and Alexa fluor (red) for CD133). The tissues were counter-
stained with DAPI (E-F) Merged image of CXCR4, CD133 and DAPI (G-H). (Magnification in 60X).
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FIG. 3: RT-PCR analysis shows CXCR4 & CD133 m-RNA expression in human gastric tissues. A) CXCR4 m-RNA transcript was amplified in
normal and carcinoma tissue; B) CD133 m-RNA transcript was amplified in normal and carcinoma tissue; C. β-actin m-RNA transcript was
amplified in normal and carcinoma tissue.
TABLE 3: Relationship between expression of CXCR4 and CD133 in gastric cancer.
Expression of
CXCR4
n=90 Expression of CD133
0 (5) 1+ (12) 2+ (26) 3+ (47)
0 4 2 1 1 0
1+ 14 1 2 9 2
2+ 27 2 7 12 6
3+ 45 0 2 4 39
a. Significant Positive correlation found in between CXCR4 expression and CD133 expression in gastric cancer (χ2 = 58.657) (p<0.001**).
TABLE 4: Expression of CXCR4 and correlation with clinicopathological factors in gastric cancer.
Parameters n CXCR4
(+ve)
CXCR4
(-ve)
χ2 p- value
Age
<=50
>=50
55
35
52
33
3
2
0.003 0.958
Gender
Male
Female
68
22
66
19
2
3
3.624 0.057
Tumor Position
Upper
Middle
Lower
25
30
35
24
28
33
1
2
2
0.188 0.910
Tumor Size
<4
4-8
>8
38
28
24
26
23
23
12
5
1
7.025 0.030*
Tumor Depth
Mucosa
Sub Mucosa
Muscularis Propia
Subserosa
14
35
26
15
8
30
24
14
6
5
2
1
10.113 0.018*
Lymphatic Invasion
(+ve)
( -ve)
54
36
39
18
15
18
4.59 0.032*
Node Metastasis
(+ve)
(-ve)
51
39
37
18
14
21
6.48 0.011*
a. *Denotes significance at 5% level
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TABLE 5: Expression of CD133 and and correlation with clinicopathological factors in gastric.
Parameters n CD133
(+ve)
CD133
(-ve)
χ2 p-value
Age
<=50
>=50
55
35
54
32
1
3
2.297 0.130
Gender
Male
Female
68
22
66
20
2
2
1.480 0.224
Tumor Position
Upper
Middle
Lower
25
30
35
24
29
33
1
1
2
0.232 0.891
Tumor Size
<4
4-8
>8
38
28
24
24
22
22
14
6
2
6.673 0.036*
Tumor Depth
Mucosa
Sub Mucosa
Muscularis Propia
Sub serosa
14
35
26
15
9
30
24
15
5
5
2
0
9.120 0.028*
Lymphatic Invasion
(+ve)
( -ve)
54
36
38
17
16
19
4.87 0.027*
Node Metastasis
(+ve)
( -ve)
51
39
39
20
12
19
6.21 0.013*
a. *Denotes significance at 5% level
Correlation between CXCR4 and CD133 expression in gas-
tric adenocarcinoma
The correlation between CXCR4 and CD133 expression in
gastric adenocarcinoma tissues were shown using spearman
rank correlation study (Table 3). Statistically significant posi-
tive correlation was found between CXCR4 and CD133 ex-
pression in gastric adenocarcinoma (χ2= 58.657).
CXCR4 and CD133 m-RNA expression in gastric cancer and
adjacent normal gastric mucosa
RT-PCR analysis was done to show the presence of CXCR4
and CD133 m-RNA in gastric tissue samples. In gastric ade-
nocarcinoma tissues m-RNA transcript was present for both
CXCR4 and CD133 whereas adjacent normal gastric tissue
was showing very mild expression (Figure 3). β- actin was
used as positive control.
Relationship between CXCR4 & CD133 expression and
clinicopathological factors
In the multivariate analysis, the expressions of CXCR4 and
CD133 were both unrelated to gender, age of the patient,
and position of the tumor but had relationship with size of
the tumour and depth of the tumour. The expression of
CXCR4 and CD133 also correlated with lymphatic invasion
and node metastasis. Both CXCR4 (p<0.05*) & CD133
(p<0.05*) expression and tumor size correlated significantly
and strongly. The depth of the tumor and expression of
CXCR4 (p<0.05*) and CD133 (p<0.05*) was also correlated
significantly and strongly. Lymphatic invasion of the tumor
and expression of CXCR4 (p<0.05*) and CD133 (p<0.05*)
were correlates significantly. Expression of Node metastasis
and CXCR4 (p<0.05*) and CD133 (p<0.05*) expression were
also correlated significantly (Table 4 and Table 5).
Discussion
Tumor prognosis is a dynamic process involving multiple
molecular and cellular mechanisms. CXCR4 expression has
been studied in breast cancer, prostate cancer, liver cancer
and renal cancer. In this study, analysis of expression pattern
of CXCR4 demonstrates the role of migratory CSC in inva-
siveness of gastric cancer. CXCR4 positive staining was found
in 94.44% (85/90) gastric cancer samples which was higher
than non-malignant tissues (p <0.001**). In breast cancer,
presence of CXCR4+ cell indicates existence of cancer stem
cells and corroborates its potential role in the acquisition of
more aggressive tumor features.12 In concomitant to this re-
port our study also suggests that increased expression of
CXCR4 in cytoplasm of cancer cells could be associated with
invasiveness of the disease.
Our RT-PCR analysis demonstrates that CXCR4 expression is
increased in adenocarcinoma than that of normal gastric
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mucosa. There was no correlation found between CXCR4
positivity and gender, age of the patient and position of the
tumor. Meanwhile, as we are found CXCR4 positivity was
significantly correlated with tumor size (p<0.05*), depth of
the tumor (p<0.05*), lymphatic invasion (p<0.05*) and node
metastasis (p<0.05*), was consistent with the study of Jun
Miki et al. in prostate cancer and the study by Satoshi et al.
in intestinal type gastric carcinoma.13,14 Distinct im-
munostaining pattern of CXCR4 in cytomembrane and/or
nucleus is associated with high tumor stage of liver carcino-
ma and metastasis of ranal cancer.15, 16 In the light of this
report our results indicate that high expression of CXCR4
may be correlated with symptomatic and advanced stages of
disease and suggesting their definitive role in prognosis of
the disease.
CD133 was considered as one of the most prominent CSC
marker which is associated with cell movement and asym-
metric cell division. CD133 was found to be over expressed
in hepatocarcinoma, gastric cancers, colorectal cancer, pan-
creatic cancer and other types of cancer. In hepatocellular
carcinoma, presence of CD133+ staining in minor popula-
tions of cells may be indicative of cancer stem-like cells
which lead to tumor recurrence and metastasis.17 In the light
of these report our study also showed that increased expres-
sion of CD133 in 95.55% (86/90) gastric cancer samples
which was higher than non-malignant tissues (p <0.05*) and
our RT-PCR data also suggests that the expression of CD133
is increased in adenocarcinoma than in normal gastric tissue.
These findings suggest that CD133 can be considered as CSC
marker for gastric cancer and its expression are correlated
with malignant progression and suggesting their definitive
role in cancer tissues. The results of our study are similar to
that reported by Ji-wei Y in gastric carcinoma18, a study by
Horst D, who established CD133 expression as a prognostic
marker in colorectal cancer19 and the study by Harmaann in
CD133+ pancreatic CSCs10. There was no correlation found
between CD133 positivity and gender, age of the patient and
position of the tumor. Our study also showed that CD133
positivity was significantly correlated with tumor size
(p<0.05*), depth of the tumour (p<0.05*), lymphatic invasion
(p<0.05*) and node metastasis (p<0.05*). From these observa-
tions, it can be concluded that high cytoplasmic expression
of CD133 is correlated with poor prognosis, invasion and
higher recurrence rates of the malignant cells.
In this study we have also analyzed the expression pattern of
CXCR4 in the distinct population of CD133+ cell in gastric
cancer tissue. In the malignant tissue, 92.22% of CXCR4+
cells were expressing CD133. In colon cancer cell,
CXCR4-expressing CD133+ cells from the primary tumour
region might play significant role in recruitment of
metastasing cells.20 In concomitant to this data our findings
also showed the presence of CXCR4+ CD133+ cells which
might transmit the signal for creating receptive microenvi-
ronments and followed by recruitment of metastasizing cells.
Our findings were similar with a study by Shan-shan et al.,
which indicate the potential involvement of CXCR4 and
CD133 in CRC metastasis to the liver in vitro.21 According to
our study, CXCR4 and CD133 protein expression in gastric
cancer displayed a significant correlation, which pointed out
co-expression of CXCR4 & CD133 is associated with higher
migratory and invasive capacities of tumor cells and might
play an important role in the migration of cancer stem cell.
Conclusion
In conclusion, our data support the previous studies which
analyze expression of both CD133 and CXCR4 in solid tu-
mours. The increased expression of CXCR4 and CD133 in
adenocarcinoma implies their possible tumour inducing ca-
pacities in human gastric carcinoma. This study also suggests
that increased co-expression of CXCR4 & CD133 could be
considered as migratory cancer stem cell and is associated
with poor prognosis and invasion of gastric cancer. Moreo-
ver, extensive studies on regulation of expression of these
markers may reveal their possibilities as therapeutic implica-
tion.
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